US Representative

Christopher Smith 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 11)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3925

Introduced
6/7/23  
Refer
6/7/23  
Youth Coastal Fishing Program Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3940

Introduced
6/9/23  
Neighborhood Homes Investment Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3974

Introduced
6/9/23  
Securing Our Airspace from Reconnaissance Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB398

Introduced
1/20/23  
Refer
1/20/23  
Protecting Life and Integrity in Research Act of 2023 This bill restricts research that uses human fetal tissue from an induced abortion. Specifically, it prohibits the Department of Health and Human Services from conducting or supporting such research. Additionally, the bill applies requirements on the research of transplantation of fetal tissue for therapeutic purposes to research on fetal tissue in general. The bill also prohibits soliciting or acquiring a donation of human fetal tissue from an induced abortion, other than for purposes of an autopsy or burial.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3991

Introduced
6/9/23  
Small Business Paperwork Savings Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3998

Introduced
6/9/23  
Refer
6/9/23  
Jackie Walorski Enhancing Necessary Data on Illegal School Bus Passing Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4014

Introduced
6/12/23  
Refer
6/12/23  
Safe Skies Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4021

Introduced
6/12/23  
Refer
6/12/23  
Fair and Open Skies Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4090

Introduced
6/14/23  
Refer
6/14/23  
Fire Grants and Safety Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4128

Introduced
6/14/23  
Payment Choice Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4137

Introduced
6/14/23  
Refer
6/14/23  
Make American Flags in America Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4175

Introduced
6/15/23  
Refer
6/15/23  
REPO for Ukrainians Act Rebuilding Economic Prosperity and Opportunity for Ukrainians Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4181

Introduced
6/7/23  
To designate the area between the intersections of International Drive, Northwest and Van Ness Street, Northwest and International Drive, Northwest and International Place, Northwest in Washington, District of Columbia, as "Tiananmen Square Memorial Boulevard", and for other purposes.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4261

Introduced
6/21/23  
Refer
6/21/23  
ARC Act of 2023 Amputation Reduction and Compassion Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)